Look back at the British research-peptide market in 2025 and the same two things keep arriving: a regulatory floor that quietly tightened, and a wave of new suppliers, products and payment-method changes that the market is still catching up with. This is the field guide we wish we'd had at the start of the year, written from the desk at the end of it.
What follows is six sections, regulation, supply, the GLP-1 spillover, the retreat of the payment processors, the new molecules, and a short look ahead at 2026. It is the longest single piece we have published, and it is the piece readers have written in to ask for most. None of it is a recommendation. All of it is what we wish more of the market would talk about openly.
I. The regulatory weather
The single most important thing that happened in UK peptides in 2025 did not happen on the supplier side at all. It happened in regulators' inboxes. The MHRA, the ASA and Trading Standards each, in their own register, started paying noticeably closer attention to how peptides are marketed and sold to British buyers, and the temperature of the official correspondence shifted from "advisory" to "noticed".
The ASA's posture is the easiest one to measure, because the rulings are public. The standards authority published a string of decisions through 2025 against UK-facing sellers whose copy crossed the line between research framing and medicinal implication, outcome claims phrased as testimonials, dosage suggestions buried in product descriptions, before-and-after marketing dressed up as a research note. The rulings did not, on their own, change anyone's business overnight. What they did was establish, on the record, what the line is, and what falls on the wrong side of it.
The MHRA's approach in 2025 was less public and arguably more consequential. Several UK suppliers we have spoken to confirmed receiving informal letters of guidance through the year, raising questions about marketing copy and product framing without yet escalating to formal action. The pattern is clear enough to call it a pattern. Whether the agency will move from informal correspondence to formal consultation through 2026 is the open question. Most informed reading is that it will, and that the eventual consultation will focus on the limits of "research use only" labelling.
For buyers, the practical effect is small in the short term and larger in the medium term. Sites that were comfortable making outcome-shaped claims twelve months ago have, on average, quietly toned them down. Sites that have not, and are still running them at scale, are the ones to watch, those are the campaigns most likely to draw the next round of attention.
II. The supply-side shake-out
Look at the UK Companies House register for entities incorporated in 2025 with peptide-related trading names, and the numbers are stark. More UK research-peptide companies were registered in 2025 than in the previous three years combined. Most are small operations, registered in serviced offices in London W1 or Manchester, with directors who have other businesses in adjacent categories. A small number are doing genuine UK fill-and-finish work. A larger number are reseller operations rebadging product synthesised elsewhere. Distinguishing the two from a buyer's vantage point is harder than it should be, and harder than it was three years ago.
The slower story is the attrition at the older end of the market. Several long-established UK names whose websites still look the part have, in 2025, been quietly reducing catalogue size, lengthening lead times and shifting their customer service away from the public inbox. The pattern is familiar across regulated-adjacent industries; the supplier that built its reputation when the market was unregulated is the supplier least equipped to operate inside a tightening one. We expect to see one or two of these names exit the public market in 2026, either through formal closure or a quiet rebrand.
The middle of the market, where the most credible new entrants have appeared, is the most interesting story of the year. A small handful of UK-incorporated suppliers, most of them registered in 2024 or 2025, have built businesses around per-batch testing, single named labs, written supply terms, and a deliberate refusal to compete on the lowest end of the price curve. Black and White Peptides is one. Proforma Peptides is another. The pattern they share is doing the slower, paperwork-led work that the older market never had to do. Whether that pays back in 2026 is the question of the year.
III. The GLP-1 spillover
The biggest single shaping force on the UK research-peptide market in 2025 was not a peptide market story at all. It was the failure of the regulated weight-loss medicines supply chain to keep up with demand for Ozempic, Wegovy, Mounjaro and Zepbound. The downstream effect on UK research peptides was unmistakable.
Search interest for "semaglutide" and "tirzepatide" on UK-domiciled research-peptide sites multiplied through the year. Demand for analogues that have not yet completed UK clinical pathways, retatrutide and cagrilintide above all, climbed steeply through the second half. Suppliers responded as suppliers do: stocking the products that buyers were searching for, often without much editorial commentary on what the products actually are, who is producing them, or what the regulatory status of marketing them in the UK looks like.
The honest read is that the GLP-1 era has created a category of UK buyer that the research-peptide market was not designed for, a buyer who is not running a research programme, who is looking for a self-administered weight-loss option, and who is approaching the research-peptide channel because the prescribed-medicines channel is either inaccessible or unaffordable. That buyer is the buyer the regulators are most concerned about, and the buyer the marketing copy is most often (and most riskily) addressed to. The intersection is where the next ASA cases will come from, and probably the next MHRA escalation as well.
IV. The retreat of the payment processors
In the back half of 2025, three of the larger card-acquiring banks and one major online processor quietly withdrew services from a number of UK research-peptide sites. The pattern was not announced and is not yet uniform across the category, but the working assumption among suppliers we spoke to is that internal risk-rating policies tightened, partly in response to the GLP-1 spillover above, partly to the ASA rulings, partly to the broader regulatory tone.
The practical effect on the market has been a shift toward bank-transfer-only payment among smaller and newer suppliers, and a defensive doubling-down on card processing by the larger names that managed to keep their merchant accounts. Bank-transfer-only payment is not, in itself, a fraud signal, there are good operational reasons a small UK supplier might choose BACS over Stripe. It does, however, change the supplier-buyer relationship in a way that matters. There is no chargeback on a bank transfer. The trust the buyer extends is one-way, and the seller's reputation has to do the work that the card scheme would have done in a previous decade.
V. The new molecules
The science kept moving through 2025, even where the marketing copy did not. Retatrutide, the triple-agonist successor to tirzepatide, continued to generate published data through the year and remained the most-asked-about new arrival in our inbox. Cagrilintide, the long-acting amylin analogue, drew the second-most attention; the early combination data with semaglutide is the reason. Longer-acting bremelanotide variants began appearing in catalogues with very little supporting documentation.
Beyond the weight-regulation cluster, the slower and more interesting story is the return of attention to the cognitive-research peptides, Selank, Semax and the wider class of synthetic neuropeptides developed in the Soviet pharmacology programme. These have been on the margins of the UK research-peptide catalogue for years; in 2025, several mid-tier UK suppliers began listing them with proper documentation for the first time. Whether the renewed interest is durable or seasonal is unclear.
The general buyer rule still holds, more importantly in 2025 than it did in 2023: new molecule on a catalogue does not mean new molecule produced to standard. The question to ask of any newly listed peptide is not "have you got it" but "where did the synthesis happen, and what does the lot's certificate of analysis actually say". The answer separates the credible suppliers from the rebadging ones with more reliability than any marketing claim ever will.
VI. What 2026 looks like
Three forecasts, all confidence-weighted. We will come back to this piece in twelve months and mark our own homework.
First, regulation. The probability of a formal MHRA consultation on the limits of "research use only" labelling sits, on our reading of the year, well above evens for 2026. The consultation, if it comes, will not end the research-peptide channel overnight. It will draw a clearer line between credible research-supply operations and the consumer-facing rebadgers that have used the framing as cover. Suppliers that have spent 2025 tightening their compliance will read like the inevitable winners.
Second, supplier consolidation. The number of UK-registered peptide companies will, we suspect, peak in mid-2026 and then begin to fall. The combination of tighter regulation, narrower card processing and rising lab-testing standards will price out the smallest operations. The market will end 2026 with fewer suppliers, on average more competent ones, and a clearer split between consumer-facing brands and trade-supply outfits.
Third, the buyer. The reader emails we read every week are getting more sophisticated. Buyers ask about lot numbers, named labs and UKAS accreditation more often than they did at the start of 2025; they ask about product-line marketing claims less often. The market is, slowly, training the buyer it deserves. Suppliers that have spent 2025 investing in real paperwork rather than real marketing copy are the ones positioned to meet that buyer halfway. The market in 2026 will be a smaller and harder one to enter, and a more interesting one to sit inside.
For a deeper read on the framework we use to test any individual supplier against the trends sketched above, our lead essay on how to vet a UK peptide company in 2026 sets out the five checks we run on every name we cover.
The bottom line
2025 was the year the British research-peptide market grew up, slowly and unevenly. The buyer is more sophisticated. The regulators are paying closer attention. The suppliers doing the slow paperwork-led work are the ones likely to be left standing in 2027. The ones still operating like it is 2019 are running on borrowed time. We will keep covering this market at Compound Buyer, edition by edition. If there is an angle on UK peptides you'd like us to cover, write in. The next piece is already half-shaped by what readers have asked for.
